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Facioscapulohumeral muscular dystrophy (FSHD) is caused by a cascade of epigenetic events following contraction of the polymorphic
macrosatellite repeat D4Z4 in the subtelomere of chromosome 4q. Currently, the central issue is whether immediate downstream effects are local
(i.e., at chromosome 4q) or global (genome-wide) and there is evidence for both scenarios. Currently, there is no therapy for FSHD, mostly
because of our lack of understanding of the primary pathogenic process in FSHD muscle. Clinical trials based on suppression of inflammatory
reactions or increasing muscle mass by drugs or training have been disappointing. A recent, probably the first evidence-based pilot trial to revert
epigenetic changes did also not provide grounds for a larger clinical study. Clearly, better disease models need to be developed to identify and test
novel intervention strategies to eventually improve the quality of life for patients with FSHD.
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Autosomal dominant facioscapulohumeral muscular dystro-
phy (FSHD) is a common myopathy with a unique epigenetic
etiology. With almost complete linkage to the distal end of
chromosome 4q (4q35), this disorder is not caused by structural
mutations within the disease gene as commonly seen in mono-
genetic traits, but rather involves a complex cascade of epigene-
tic events following contraction of a subtelomeric macrosatellite
repeat. This review aims to discuss recent advances in our
understanding of FSHD pathology viewed against its clinical
heterogeneity. We will also discuss recent clinical trials and
speculate on novel directions for therapy.
2. Clinical features
Patients usually present with symptoms related to weakness
of the scapula-fixators; rarely do they report onset of the disease
in the facial, foot-extensor or pelvic girdle muscles. Shoulder
girdle weakness characteristically is visible as an asymmetrical⁎ Corresponding author. Tel.: +31 71 526 9480; fax: +31 71 526 8285.
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doi:10.1016/j.bbadis.2006.05.009scapula alata and pectoralis muscle atrophy. An initially fairly
normal deltoid muscle contributes to the distinctive high risk of
the scapula on elevation of the arms [1,2]. Another very typical
feature is the asymmetrical facial weakness. If subtle facial
weakness is taken into account more than 90% of patients reveal
facial muscle involvement. In large families 30% of gene carriers
have no complaints and often do not know they are affected. A
number of patients do not progress beyond shoulder muscle
involvement and in large families approximately half the pa-
tients progress to pelvic girdle weakness, usually after extension
of the weakness to the abdominal, foot-extensor and upper-arm
muscles. Landouzy and Dejerine described the extreme hyper-
lordosis as a characteristic end-stage of this course [3].
A patient usually recognizes the disease in his teens but an
extreme variation in onset is reported ranging from early infancy
to late fifties, even within a family with all affected members
carrying the same genetic lesion. When the disease progresses to
the lower limbs again the rate of progression is quite variable [2].
Occasionally long periods of standstill have been reported. A
mild gender effect has been noted by several authors; women
tend to be more often asymptomatic, have a slightly later onset
and a somewhat milder course of the disease [4]. Muscle pain
and fatigue are frequently reported; dysphagia is rare, as is
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defects have been observed, although most authors claim no
cardiac involvement. Extra-ocular and masticatory weakness are
no part of FSHD and point to other diagnoses. Lingual muscle
involvement, probably not progressive, has been mentioned in
early onset FSHD [6].
Contractures are rare with exception of ankle contractures.
A subclinical high tone hearing loss and a subclinical retinal
vasculopathy have been described as part of the disease [7,8].
Rarely, and almost exclusively in early onset disease, they
become symptomatic.
Early, i.e., infantile, onset has in the past been thought of as an
independent entity but has turned out to be the more severe end
of the clinical spectrum with usually small residual D4Z4 repeat
sizes (see genetic defect), while the other end of the spectrum
reveals oftenminimally to mildly affected patients with probably
more frequently non-penetrant gene carriers in these families.
The characteristics of FSHD often lie in subtle signs when a
physician is confronted with a patient with a facio-scapulo-
humeral syndrome. But the rarity of the disorders in the diffe-
rential diagnosis make that FSHD should be considered first [2].
Genetic diagnostics is recommended as the first step and, only
when FSHD has been ruled out, family examination, EMG and
muscle biopsy are indicated.
3. Genetic defect
Linkage for FSHD was established in the early 1990s by a
genome-wide microsatellite scan in a few Dutch families with
autosomal dominant FSHD. FSHD was found to link to 4q35,
which was confirmed in other families worldwide [9–13]. By
means of positional cloning the genetic defect in FSHD was
identified as a reduction of the size of an EcoRI fragment on
genomic DNAwhen hybridised with probe p13E-11. This probe
was derived from a cosmid clone mapping to 4q35 that was
isolated in a screen for homeobox-like sequences. In familial and
isolated FSHD cases this large and polymorphic EcoRI fragment
was reduced below the size of 28 kb [14,15]. Not much later, the
genetic defect in FSHDwas established as a partial deletion of an
integral number of repeat KpnI fragments, designated D4Z4
[16]. Screening of large series of control individuals and FSHD
patients showed that the D4Z4 repeat normally varies between
11 and 100 units, giving rise to EcoRI fragments of 40>300 kb,
while >95% of FSHD patients carried one allele of 1–10 units
(EcoRI fragments of 10–38 kb) [17]. FSHD patients with one
allele completely devoid of D4Z4 units have never been reported
andmonosomy 4q does not cause FSHD predicting a critical role
for D4Z4 in FSHD pathogenesis [18]. From now on, DNA
diagnosis for FSHD became available. Over recent years, it has
become apparent that there are many complications to this rela-
tive straightforward diagnosis of FSHD, which we will briefly
discuss below.
First, it was shown that an almost identical and equally poly-
morphic repeat resides in the subtelomere of chromosome 10q as
a result of an ancient duplication [19,20]. Repeat contractions on
chromosome 10q are non-pathogenic [21,22]. Second, appa-
rently unconstrained exchanges between repeat units on bothchromosomes can be encountered in the population and
although generally the precise allele constitution for all
chromosomes 4 and 10 can be precisely defined, even for the
most complicated repeat exchanges, it needs sophisticated
follow-up experiments often not available in diagnostic centres.
Repeat exchanges between chromosomes 4 and 10 can be
encountered in approximately 10% of the population, but despite
this dynamic behaviour, FSHD is uniquely linked to chromosome
4 and contractions of translocated 4-type repeat units on
chromosome 10 have never been observed in FSHD [23–25].
In addition to a contraction of D4Z4, at least one yet to be
identified cis-element seems to be necessary to develop FSHD.
A biallelic variation was discovered for the 4q subtelomere [26].
Both variants, 4qA and 4qB, are almost equally common in the
population, but FSHD alleles are always of the 4qA-type, except
for a few very rare cases in which the disease allele failed to
hybridise to the 4qA and 4qB probe [27,28]. While both variants
show an equal variation is size and an equal somatic instability, it
was concluded that additional elements on 4qAwere necessary
to cause disease or 4qB chromosomes carry elements that
prevent FSHD. Indeed, several families have now been reported
in which FSHD-sized 4qB alleles segregate in healthy indi-
viduals [29,30]. Both variants differ by few insertion deletion
events, the most prominent being a large block of beta satellite
DNA immediately distal to D4Z4 on 4qA alleles [26]. Although
initially the elements that distinguish 4qA from 4qB were
assigned to the region distal to D4Z4, a region of approximately
60 kb ending in the telomere repeat, more recent studies show
that these sequences distal to D4Z4 are in strong linkage
disequilibrium with sequences immediately proximal to D4Z4.
These studies have also indicated that 4qA and 4qB alleles
infrequently exchange material in the regions proximal and
distal to D4Z4 feeding the assumption that both alleles are
functionally different [31].
In a small percentage of FSHD cases, the disease allele can be
easily overlooked as the deletion in these patients extends in pro-
ximal direction and includes the probe region p13E-11 [23,32].
While solutions have been provided to overcome this problem in
DNA diagnosis, these patients may be very instrumental in further
defining the minimal requirement to develop disease.
In summary, in >95% of FSHD cases, a contraction of D4Z4
below the threshold of 11 units on a 4qA allele is associated with
disease. For the remainder of patients no locus has been iden-
tified although recently some evidence for linkage to chromo-
some 15 was presented in one family [33,34]. Some candidate
genes, most notably those encoding for components of the D4Z4
repressor complex (see epigenetic disease mechanism) and
MYOD1, have been excluded as candidate genes [35]. However,
recently it was shown that some of these cases share an epi-
genetic phenomenon with 4qter-linked FSHD and therefore in
these cases, the disease mechanism also acts through chromo-
some 4 (see epigenetic disease mechanism). Other cases have
wrongly been attributed to genetic heterogeneity as they repre-
sent cases with proximal extended deletions preventing iden-
tification of the contracted allele by standard DNA diagnosis.
Whether or not true non-4q-linked cases for true large non-4q-
linked families exist remains to be established.
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After the identification of the primary genetic lesion in FSHD,
research focused on the gene content within D4Z4 assuming that
contraction of D4Z4 directly impaired the structure or function of
a gene contained within D4Z4. Each D4Z4 units has sequence
features characteristic for a CpG island with a GpC:CpG ratio of
0.8. It also contains several repeat sequences suggestive for a
heterochromatic structure. Moreover, a putative gene was iden-
tified within each unit designated DUX4 (for double homeobox
gene 4) [36–39]. Despite many efforts, no conclusive evidence
has been presented thus far that this gene is actively transcribed in
vivo and encodes for a genuine homeobox protein. However, at
present it cannot be excluded that in specific spatiotemporal win-
dows, DUX4 is expressed.
Approximately 40 kb proximal to D4Z4, one inverted and
truncated copy of D4Z4 is located [40]. This inverted copy
defines the proximal boundary of the region of homology
between chromosomes 4 and 10 and also contains a putative
double homeobox gene DUX4C, which is absent on chromo-
some 10. Like for DUX4, no expression is documented for
DUX4C [41].
Therefore, focus shifted to understanding the chromatin
structure of D4Z4 – and possibly, a change thereof in FSHD
patients – and to the identification of candidate genes in the
region immediately adjacent to the D4Z4 repeat assuming that
the D4Z4 repeat can influence the transcriptional control of
4q35 genes. A DNA-binding complex, consisting of HMG2B,
YY1 and nucleolin, was identified that binds to D4Z4. It was
proposed that this complex acts as a local repressor and that
with insufficient binding due to the loss of sufficient binding
sites, local genes became transcriptionally upregulated. Con-Fig. 1. Complex (epi)genetic cascade causing FSHD. FSHD is caused by contract
chromosome 4q to a residual size of 1–10 units. This contraction is paralleled by DN
DNA) and other chromatin changes including a possible partial loss of the D4Z4 repr
one of the two common variants of 4qter, the 4qA allele (hatched box). D4Z4 cont
functional domains are responsible for this difference. In a small proportion of pati
D4Z4 is also observed unrelated to contraction. These changes in chromatin structur
global deregulation of transcription. Several genes within the vicinity of D4Z4 have b
include FRG2 (at 37 kb distance), FRG1 (at 120 kb distance) and ANT1 (at approxsistent with this view was their observation that in FSHD
muscle three genes, FRG1, FRG2, and ANT1, were transcrip-
tionally upregulated. This upregulation was distance-dependent
with the gene closest to D4Z4 being most significantly
upregulated and D4Z4 repeat size-dependent: patients with
smaller residual repeat sizes showed greater upregulation than
patients with longer residual repeat sizes. Moreover, cell
cultures devoid of members of the repressor complex showed
transcriptional upregulation of FRG2 [42].
However, several independent follow-up studies using
different quantitative expression analysis techniques failed to
reproduce the transcriptional upregulation of above-mentioned
genes in FSHD skeletal muscle [43,44]. Expression levels
varied from unchanged to upregulated or even downregulated
compared to normal muscle. This issue is still largely
unresolved but may partly be explained by the different
technological approaches and variation in source of RNA
(muscle pathology, duration of disease, etc.). At protein level,
only limited data are available as discussed below for the
individual candidate genes (Fig. 1).
Studies of DNA methylation showed that D4Z4 at disease
alleles is significantly hypomethylated. Employing two methy-
lation-sensitive restriction enzymes, normal alleles showed
average methylation levels of approximately 50% while in
FSHD alleles, methylation levels were on average reduced by a
factor 2. Interestingly, some phenotypic FSHD patients without
contraction of D4Z4 also showed pronounced hypomethylation
of D4Z4. In contrast to 4q-linked FSHD, where the hypo-
methylation was restricted to the contracted (disease) allele, in
phenotypic FSHD, both chromosomes 4 were hypomethylated
at D4Z4. Non-penetrant gene carriers of 4q-linked FSHD
families also showed hypomethylation at D4Z4. Collectively,ion of the polymorphic D4Z4 repeat (triangles) in the subtelomeric domain of
A hypomethylation (open circle: unmethylated DNA, closed circle: methylated
essor complex. To exert a pathogenic effect, D4Z4 contractions need to occur on
ractions on the 4qB allele are non-pathogenic and it is currently unclear which
ents, the so-called phenotypic or non-4qter-FSHD patients, hypomethylation of
e are hypothesized to cause a cascade of downstream effects including local and
een investigated for their role in the development of FSHD. Most notably, these
imately 3 Mb distance).
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not sufficient to cause FSHD [45].
Although overall FSHD alleles are hypomethylated at D4Z4,
individual methylation levels are very diverse. To explain inter-
and intrafamilial variation in disease severity, it was postulated
that variation in residual D4Z4 methylation may influence the
natural course of disease. Although in a small set of patients no
direct linear relationship could be established between D4Z4
hypomethylation and disease severity, it is interesting that the
smallest FSHD repeats (which are commonly associated with
the severest phenotypes) showed the lowest levels of D4Z4
methylation. Clearly, more comprehensive methylation assays
need to be developed to address the issue of D4Z4 methylation-
dependent severity [46].
Other studies of chromatin structure of 4qter show that the
FSHD region should be considered as unexpressed euchroma-
tin, rather than heterochromatin. Gene expression studies and
histone H4 acetylation levels in regions immediately adjacent
to D4Z4 and in more proximal direction did not show evidence
for a change in chromatin structure emanating from D4Z4
between cell lines from controls and FSHD patients. Also other
markers for heterochromatin, including co-localization studies
of 4qter with DAPI bright foci or enrichment of 4qter for
histone H3 trimethylated at lysine 9 and heterochromatin
protein 1α, were consistent with D4Z4 being unexpressed
euchromatin [43,47].
A few genes have been considered as good candidate genes for
FSHD based on their localization and/or function. The gene that
was first investigated for its potential role in FSHD is ANT1 gene
coding for the adenine nucleotide translocator. This gene is
located at minimal 3.5 Mb distance of D4Z4 and encodes for a
protein that facilitates the export of ATP over the mitochondrial
membrane [48–50]. Its high expression in skeletal and heart
muscle and its involvement in several neuromuscular disorders
made it an attractive candidate gene but expression studies to
determine whether ANT1 levels are increased in FSHD muscle
remain controversial. Recently, evidence was presented that
ANT1 protein levels were increased in asymptomatic and
symptomatic muscle [51], but additional studies are necessary
to explore the involvement of ANT1 in FSHD as transgenic mice
muscle-specifically overexpressing ANT1 do not seem to develop
muscular dystrophy [52].
Another gene which involvement was tested in FSHD is
PDLIM3. This gene encodes for the muscle-specific actinin-
associated LIM protein (also known as ALP) but Western blot
analysis and immunohistochemistry did not provide evidence for
differential expression of the PDLIM3 protein [53,54]. Pdlim3
knockout mice show no evidence for muscular dystrophy but
present with right ventricular chamber dilatation, making this
protein an unlikely candidate for FSHD [55].
The gene closest to D4Z4 is FRG2. The FRG2 gene, at 37 kb
distance from D4Z4 encodes a putative nuclear protein of un-
known function [56]. Although specifically upregulated in dif-
ferentiating muscle cell cultures of FSHD patients, its absence in
some patients with proximally extended deletions, makes this
gene a less attractive candidate [32]. Also, mice overexpressing
FRG2 do not present with muscular dystrophy [52].The last candidate gene investigated at 120 kb distance from
the D4Z4 repeat is FRG1. This gene is highly conserved in
vertebrates and non-vertebrates and encodes a nuclear protein.
All evidence suggests that FRG1 is a spliceosomal protein, but
the exact function remains to be elucidated [57–59]. Interest-
ingly, the subtelomeric localization of FRG1 is hominoid-
specific. Due to an ancient translocation in all species but ho-
minoids FRG1 is located in a gene-rich domain flanked by
PCM1 and ASAH1 [60]. Since its translocation to the 4q sub-
telomere, several duplication events have occurred yielding
almost identical copies of FRG1 at many chromosomes, some
of which also seem to be actively transcribed [58,61].
Expression studies of FRG1 in FSHD muscle are contro-
versial. Various studies employing semi-quantitative radioactive
RT-PCR, quantitative RT-PCR, expression arrays and even
allele-specific RT-PCR on affected muscle of FSHD patients
yielded evidence varying from no change in expression levels to
25-fold upregulation or even 5-fold downregulation [42–44,58].
Clearly, the different techniques used and the natural variation in
the source of RNA (site of biopsy, pathology, disease duration,
severity) has contributed to this controversy. However, with the
recent observations in the transgenic FRG1 mice (see below),
solving the issue of FRG1 expression in FSHD muscle has even
become more important.
Mice that overexpress FRG1 in skeletal muscle develop
muscular dystrophy with a severity proportional to the level of
overexpression. Three transgenic lines were generated over-
expressing FRG1 10-, 25- and 45-fold, respectively, compared
to the endogenous Frg1 levels. While the mice with lowest
overexpression did not show significant pathology, mice with
intermediate or high FRG1 levels showed increasing pathology.
Interestingly, missplicing of specific mRNAs was observed in
skeletal muscle of these mice further corroborating on the ob-
servation that FRG1 is a spliceosomal protein. Missplicing was
also observed in C2C12 cells stably expressing HA-tagged
FRG1 and in muscle cell cultures of FSHD patients [52]. How-
ever, we did not find evidence for missplicing in RNA from
affected muscle of FSHD patients (unpublished data). Misspli-
cing of muscle-specific mRNAs has been reported earlier in
myotonic dystrophy (DM) raising the intriguing possibility of a
commonality between FSHD and DM. However, until the con-
troversy of FRG1 upregulation is truly solved, it is too early to
assign FRG1 as the causative gene for FSHD.
5. Studies of nuclear organization
An entirely different and equally exciting finding relates to
commonalities that FSHD may share with the nuclear envelope
dystrophies. Chromosomes occupy distinct territories in the
mammalian nucleus. These chromosome territories are often a
reflection of their gene density, transcriptional activity, replica-
tion timing, and chromosome size [62,63]. Unlike all other
chromosome ends studied, including the highly homologous
10qter, 4qter is preferentially localized in the outer nuclear rim,
independent of cell type and chromosome territory effects. Not
D4Z4 itself, but sequences proximal to D4Z4 seem to be neces-
sary and sufficient for this perinuclear localization [64,65]. This
190 S.M. van der Maarel et al. / Biochimica et Biophysica Acta 1772 (2007) 186–194may explain the different nuclear localization of 10qter as the
homology between 4qter and 10qter only extends 40 kb pro-
ximal to D4Z4. Although no difference was observed in loca-
lization of normal and FSHD chromosomes, the perinuclear
localization of 4qter is largely lost in fibroblasts lacking lamin
A/C [64]. The nuclear envelope dystrophies, including X-linked
and autosomal dominant Emery–Dreifuss muscular dystrophies
(EDMD) are caused by mutations in emerin and lamin A/C,
respectively, thus raising the intriguing possibility that FSHD is
related to these nuclear envelope muscular dystrophies [66].
Indeed, recent expression studies showed that the transcriptome
fingerprints of EDMD and FSHD are highly similar [67].
6. Clinical trials
In 1997 the natural history of FSHD was described based on
a careful systematic follow-up of 81 patients. This study also
calculated that a two armed clinical trial with a power of 80% to
detect arrest of progression after 1 year would require 160 pa-
tients in each arm [68].
This observation led to the strategy of pilot-studies in a small
number of patients aiming for large effects before deciding on
large trials, and it pushed for a search for biomarkers as surro-
gates to follow before planning large-scale studies.
First, prednison 1.5 mg/kg/day was tested in an open label
study in 8 patients, because of the frequent observation of in-
flammatory infiltrates in muscle biopsies. The hope was for a
similar effect as in Duchenne muscular dystrophy. However,
after 3months no significant changes in muscle mass andmuscle
strength were noted [69].
Subsequently albuterol was studied because of its known
effect on muscle protein-metabolism and contractility, and expe-
riences in sports medicine. A slightly successful 3-month open
label pilot was followed by a randomized placebo-controlled
trial in 90 patients testing two doses (16 and 32mg/day) during 1
year. After 52 weeks mean strength in the treatment and in the
placebo group was the same. As the treatment group showed
initially a small gain in strength (similar to the pilot condition) it
was suggested that the anabolic effect wears off over time [70].
A similar study testing albuterol 16 mg/day for 6 months was
carried out in the Netherlands. The results showed significant
improvement of isometric muscle strength in 7 out of 12 muscle
groups and increased muscle volume but there was no positive
effect on pain, experienced fatigue, functional status (Sickness
Inpact Profile) and on psychological distress [71].
Creatine plays an important role in the energy metabolism of
skeletal muscle food supplement as patients with muscular dys-
trophies were reported to have lower endogenous muscle stores.
A randomized double blind, cross-over study in 32 patients
(12 FSHD) showed a significant positive effect on muscle
strength and activity scores for the group as a whole [72]; ana-
lysis of the FSHD patients only revealed no positive effects.
However, this study was deemed too small and too short for firm
conclusions [73].
Based on personal observations Lefkowitz and Lefkowitz
argued for a role of calcium-entry-blockers in the treatment of
FSHD [74]. An open label pilot-study of diltiazem 30 mg TIDwas carried out in 20 patients. Muscle strength and muscle mass
was not changed significantly after 6 months. No future studies
were suggested [75].
Because we recently demonstrated that the shortened D4Z4
repeat in FSHD is hypomethylated we designed an open-label
pilot to study the effects of folic acid (5 mg/day) and methionine
(1 gm TID) on D4Z4 methylation after 12 weeks in 9 FSHD
patients and in 6 healthy controls. No significant changes in
methylation level of D4Z4 were found in patients or controls
(v.d. Kooi unpublished).
At present a clinical trial is under way testing recombinant
myostatin-neutralizing antibody treatment in a number of
Becker, limb-girdle and FSH muscular dystrophy patients. As
myostatin negatively regulates muscle mass, blocking myostatin
might reverse a muscle wasting condition.
The effects of training of muscle strength in FSHD have been
under discussion for years. Only recently training was evaluated
in a prospective randomized controlled, single blinded study
[71]. Training for 6 months was followed by a double-blinded
addition of albuterol 16 mg/day. Training included dynamic and
isometric exercises. Maximum voluntary isometric strength was
unchanged at 52 weeks in the elbow flexors but decreased –
though not significantly – in the foot dorsiflexors. Dynamic
strength tests of 52 weeks showed a significant positive effect in
the elbow flexors only. The differences in response between the
elbow flexors and foot dorsiflexors remained unclear. It was
concluded that training does not inflict harm to FSHD muscles.
Similarly, a 12-week aerobic training programme on a cycle
ergometer at a heart rate corresponding to a work at 65% of
VO2-max in 8 FSHD patients showed no adverse affects on
quadriceps histology. Maximal oxygen uptake and workload
improved significantly and most patients reported subjectively
improved strength and activity [76]. Fatigue did not improve,
suggesting that fatigue is different from deconditioning. As
most patients in this study were mildly affected further training
studies in more severely affected patients appear desirable.
7. Possibilities for therapy
All trials thus far for FSHD have been rather disappointing. If
any positive effect was observed, generally it did not persist or
was too subtle to significantly improve the quality of life for the
patients. At present, molecular studies are not sufficiently ad-
vanced to suggest new therapeutic handles on the primary or
early pathogenic mechanisms. Clinical trials so far have ad-
dressed end of cascade features and fairly advanced stages of
muscle pathology. A combination of presently known therapies
is not likely to yield a significant improvement in muscle per-
formance. The one combination trial of training and albuterol did
not show an additive effect [71].
Nevertheless, our observations in mosaic patients seem to
indicate that we may only need to correct the pathogenic me-
chanism in a proportion of cells to slow down or halt disease
progression. Individuals mosaic for the disease allele due to a
mitotic contraction of D4Z4 only have a proportion of affected
cells and generally present with a much milder, or even (almost)
asymptomatic, phenotype [77]. Most notably in mosaic females,
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after the diagnosis of an affected child that inherited the disease
allele. Although there seems to be a correlation between the
severity and a combination of proportion of affected cells in PBL
and residual repeat size, only muscle of a single mosaic female
was available to demonstrate that muscle and blood show equal
proportion of affected cells [30]. Clearly, additional mosaic
cases need to be studied to compare mosaic cell proportions in
blood and muscle and to define the minimal proportion of nor-
mal nuclei in FSHD muscle to exert beneficial effects.
Interestingly, it was recently demonstrated that muscle cell
cultures derived from unaffected muscle (vastus lateralis) of
FSHD patients were morphologically and behaviourally indis-
tinguishable from healthy muscle cell cultures. These cells had
normal morphological appearance as assessed by light micro-
scopical analysis and were able to differentiate to myotubes with
similar efficiency as wild type muscle cells. Moreover, when
injected in immunodeficient mice, these cells were able to
participate in muscle regeneration processes [78]. These data are
in marked contrast to earlier studies of FSHD muscle cell
cultures derived from affected muscle. These cells displayed a
necrotic phenotype with enhanced susceptibility to oxidative
stress [79]. While these studies indicate that there may be a
functional difference between muscle cells from affected and
unaffected muscle, they also demonstrate the possibility of au-
tologous myoblast transplantation. However, without having
corrected for the pathogenic mechanism in these cells, it is
difficult to envisage a lasting beneficial effect of autologous
myoblast transfer in affected muscle of FSHD patients. There-
fore, how can we correct this mechanism?
Owing to the complex genetic rearrangement in FSHD with
many copies of homologous D4Z4 sequences in the genome, it is
unlikely that a gene therapy approach to insert additional D4Z4
units at the disease locus is a feasible option. Therefore, other
therapeutic options that directly affect immediate downstream
mechanisms of the D4Z4 contraction should be considered.
As disease alleles are variably hypomethylated at D4Z4, we
explored the possibility of remethylating D4Z4. Several in vivo
folate depletion and repletion studies in humans have shown
positive effects on total genomic DNA methylation and
expression of methylation-regulated genes in PBL and several
body tissues [80,81]. Other studies indicate that the effect of
folate status on DNA methylation is more complex [82]. As
mentioned, in our small open trial, while in most subjects total
genomic methylation levels increased as expected, we were
unable to identify significant remethylation of D4Z4 (Van der
Kooi, unpublished).
Other approaches to correct the pathogenic mechanism in
FSHD need to come from our steadily increasing understanding
of the primary defect in FSHD and its immediate consequences.
The central issue that is emerging seems to be whether these
immediate effects are local, global, or both. Based on recent
development, arguments can bemade favouring immediate local
and global pathogenic consequences.
The loss of the D4Z4 repressor complex at the disease allele
may not only have a local effect on transcriptional repression of
4q35 genes, but it is conceivable that it may also have genomewide consequences. Clearly, the issue of transcriptional dereg-
ulation of 4q35 genes in FSHD muscle is still not resolved and a
global effect of YYunbalance may come from a recent study in
which it was shown that YY1 binds to Enhancer of Zeste 2
(Ezh2), a member of the Polycomb group proteins, which is
developmentally regulated in the myotome compartment of
mouse somites [83]. Ezh2 has histone lysine methyltransferase
activity and interacts with histone deacetylase HDAC1 to exert
transcriptional repression. In proliferating primary myoblasts,
the YY1–Ezh2 complex is located, in combination with HDAC1,
on regulatory regions of transcriptionally inactivemuscle-specific
genes. Transcriptional activation of these genes during myoblast
differentiation coincides with loss of Ezh2–YY1 at their
regulatory elements and the recruitment of the transcription factor
MyoD. As for transcriptional regulators generally a strict stoi-
chiometry is required, these observations raise the intriguing
possibility that a local unbalance in YY1 binding to D4Z4 may
have genome-wide effects in FSHD.
The hypothesis that immediate downstream effects from the
D4Z4 contraction are not limited to 4q35 is supported by tran-
scriptome and nuclear localization studies. Transcriptome analy-
sis has shown global changes in gene expression in FSHD
muscle and also provides evidence for a defect in specific stages
of muscle differentiation. Amongst the genes differentially
expressed in FSHD muscle, many of them are immediate targets
of MyoD [44]. A more recent cross-sectional transcriptome
study showed that the transcriptional profile of FSHD co-
segregatedwith that of the nuclear lamina dystrophies, caused by
mutations in emerin and lamin A/C [67]. This substantiates the
earlier proposal that, based on the consistent localization of 4qter
in the outer rim of the nucleus, and its dissociation from the
nuclear periphery in lamin A/C null fibroblasts, FSHD should be
considered as a nuclear envelope disease [64]. Locally, the
intriguing observation that muscle specific overexpression of
FRG1 in transgenic mice leads to muscular dystrophy makes
this protein a prime candidate to be further studied in relation to
FSHD.
According to Dubowitz [84], the rationale for clinical inter-
vention studies should be based on one or more of the following
premises: (1) theoretical grounds for the potential value of a drug
in relation to a hypothesis on the pathogenesis of FSHD, (2)
trials of therapeutic agents in animal models of the disease, (3)
extrapolation from the use of a drug in similar neuromuscular or
degenerative disorders, (4) extrapolation from the use of an
agent used to enhance muscle performance and recovery or to
increase muscle mass in for example sports and veterinary me-
dicine or (postsurgery) rehabilitation, (5) observations in relation
to experimental situations such as muscle tissue culture, and (6)
serendipity.
With the recent developments in FSHD, we expect trials based
on the hypothesis of FSHD pathogenesis to emerge in the years to
come. Probably, our folic acid trial was the first of this kind.
However, with the lack of a widely recognized faithful animal
model for FSHD, the development of new therapeutic agents for
FSHD is strongly hampered. For premises 3 and 4, all trials have
been relatively disappointing with only the myostatin-neutraliz-
ing antibody MYO-029 trial still ongoing. Even the observations
192 S.M. van der Maarel et al. / Biochimica et Biophysica Acta 1772 (2007) 186–194in primary muscle cell cultures of FSHD patients (5) are not
consistent and need further attention. Ideally, a faithful uniform
and (conditionally) immortal cell model needs to be developed to
explore potential therapeutic strategies. Unfortunately, the last
premise, serendipity, has not brought FSHD any luck.
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